Original Research
Published on 23 Jun 2025
The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
in Cancer Immunity and Immunotherapy
- 101 views
Original Research
Published on 23 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 23 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 23 Jun 2025
in Cancer Immunity and Immunotherapy
Review
Published on 23 Jun 2025
in Cancer Immunity and Immunotherapy
Review
Published on 23 Jun 2025
in Cancer Immunity and Immunotherapy
Review
Accepted on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Editorial
Accepted on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Systematic Review
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Review
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Review
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Jun 2025
in Cancer Immunity and Immunotherapy